Nodelman Oleg
SEC-identified person · CIK 1454385 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Aktis Oncology, Inc. AKTS | Director | filed 2026 - 2026 |
| Zymeworks Inc. ZYME | Director | filed 2025 - 2025 |
| Anaptysbio, INC ANAB | Director | filed 2021 - 2025 |
| Panacea Acquisition Corp PANA | Director · CEO and Chairman of the Board | filed 2020 - 2023 |
| Panacea Acquisition Corp. II PANA | Director · CEO and Chairman of the Board | filed 2021 - 2023 |
| Prothena Corp plc PRTA | Director | filed 2019 - 2019 |
| Kindred Biosciences, Inc. goqxve5$ | Director | filed 2013 - 2014 |
| Genvec INC GNVC | Officer | filed 2013 - 2014 |
| Avigen INC \DE avgn | Officer | filed 2009 - 2009 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.